Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an eczema cream fight a rare skin cancer?

NCT ID NCT07781449

Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 27, 2026 · Updated 3 times

Summary

This study tests whether a cream called delgocitinib, already approved for chronic hand eczema, is safe and tolerable when applied to skin affected by early-stage cutaneous T-cell lymphoma (mycosis fungoides). Up to 15 adults with stable disease will apply the cream twice daily for 16 weeks, with researchers monitoring side effects and looking for improvements in skin symptoms like itching and appearance. This is an early proof-of-concept trial focused on safety, and its results could guide larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
delgocitinib cream (Anzupgo), a JAK inhibitor applied to the skin
What this could lead to
If this works, it could offer a new topical treatment option for early-stage cutaneous T-cell lymphoma, potentially reducing symptoms without systemic therapy.
What could go wrong
This is a small, early proof-of-concept study focused on safety, not effectiveness. The cream may not improve the cancer, and side effects like skin irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women aged 18 or older at the time of consent * Histologically confirmed diagnosis of mycosis fungoides (stage IA, IB, or IIA) * Stable disease requiring palliative treatment * No change in medication for 2 months prior to study entry * Willing and able to give informed consent, obtained prior to any study-related procedures Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients (Benzyl alcohol, Butylhydroxyanisole, Cetostearyl alcohol) * Sézary syndrome (cancerous T-cells found in the blood) * Concomitant treatment with other topical/skin-directed therapies (phototherapy, radiotherapy, chlormethine gel, topical corticosteroids) * Psychiatric illness, disability, or social situation that would compromise subject safety or ability to provide consent * History of non-melanoma skin cancer (NMSC) * Atopic dermatitis or other clinically relevant dermatological diseases * Other clinically significant medical conditions, including: * Ongoing skin infections requiring antibiotics * Physical, laboratory, or vital sign abnormalities that would, in the investigator's opinion, put the subject at undue risk or interfere with interpretation of study results * Pregnancy or breastfeeding * Women of childbearing potential must use a highly effective contraceptive method

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cutaneous T-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cutaneous T-cell lymphoma Mycosis fungoides

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.